MedTrace Logo

Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics

NCT02682862 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2019-06-21

No results posted yet for this study

Summary

Single centre, open-label, random order, cross-over trial, recruited over a period of approximately 2 years. Sufficient participants enrolled to complete 16 adults. Withdrawn subjects may be replaced.

This clinical trial will assess the effects of ultra-long acting bronchodilator therapy in smoking asthmatics taking inhaled corticosteroids. This will be via a pulmonary function test called impulse oscillometry.

Conditions

Interventions

DRUG

olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg

Inhaler: 2.5 microgram tiotropium (as bromide monohydrate) and 2.5 microgram olodaterol (as hydrochloride) per puff. 2 puffs once daily

DRUG

olodaterol 2.5 mcg

Inhaler: 2.5 microgram Olodaterol (as hydrochloride) per puff. 2 puffs once daily

Sponsors & Collaborators

  • University of Dundee

    lead OTHER

Principal Investigators

  • Sunny Jabbal, Mb Chb · University of Dundee

  • Brian Lipworth, MD, Mb Chb · University of Dundee

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-11
Primary Completion
2019-05-22
Completion
2019-05-22

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02682862 on ClinicalTrials.gov